Clinical Trials
30 trialsTesting the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Johnson & Johnson Enterprise Innovation Inc.
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
FIERCE-HN
AVEO Pharmaceuticals, Inc.
INTERLINK-1
AstraZeneca
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Eastern Cooperative Oncology Group
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Radiation Therapy Oncology Group
Head and Neck Cancer Study Project in the Geriatric Population
Brown University
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
XXL_2022-01
Groupe Oncologie Radiotherapie Tete et Cou
REACH
Groupe Oncologie Radiotherapie Tete et Cou
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Shanghai Miracogen Inc.
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Bristol-Myers Squibb
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
CHANGE2
Merck KGaA, Darmstadt, Germany
KESTREL
AstraZeneca
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb
AGMT_HNO_PN
Arbeitsgemeinschaft medikamentoese Tumortherapie
2007-01
Groupe Oncologie Radiotherapie Tete et Cou
Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)
Incyte Corporation
INTERCEPTOR
Gruppo Oncologico del Nord-Ovest
De-ESCALaTE
University of Warwick
CHANCE
Merck KGaA, Darmstadt, Germany
H&N07
Associazione Volontari Pazienti Oncologici
CHANGE
Merck KGaA, Darmstadt, Germany
Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
University of Alabama at Birmingham